紫杉醇脂质体联合铂类化疗在肺腺癌患者中的应用效果  

Application effect of paclitaxel liposome combined with platinum chemotherapy in patients with lung adenocarcinoma

作　　者：赵掌权 柳士勋 张杰 ZHAO Zhangquan;LIU Shixun;ZHANG Jie(Department of Respiratory and Critical Care Medicine,the First People’s Hospital of Zhumadian,Zhumadian 463000,He’nan,China)

机构地区：[1]驻马店市第一人民医院呼吸与危重症医学科,河南驻马店463000

出　　处：《癌症进展》2025年第6期694-697,701,共5页Oncology Progress

基　　金：河南省医学科技攻关计划联合共建项目(2018020984)。

摘　　要：目的探讨紫杉醇脂质体联合铂类化疗在肺腺癌患者中的应用效果。方法采用随机数字表法将80例肺腺癌患者分为常规方案组与联合方案组,每组40例,常规方案组患者接受紫杉醇联合铂类化疗,联合方案组患者接受紫杉醇脂质体联合铂类化疗。采用流式细胞仪检测CD4^(+)、CD8^(+)水平,并计算CD4^(+)/CD8^(+),采用分光光度计比色法检测脂肪酸合成酶(FAS)、肿瘤M2型丙酮酸激酶(TuM2-PK)水平,采用酶联免疫吸附法检测血管内皮生长因子(VEGF)、细胞角质蛋白19片段抗原21-1(CYFRA21-1)、癌胚抗原(CEA)、糖类抗原125(CA125)水平。比较两组患者的T淋巴细胞亚群水平(CD4^(+)、CD8^(+)及CD4^(+)/CD8^(+))、FAS、TuM2-PK、VEGF、CYFRA21-1、CEA、CA125、临床疗效及不良反应发生情况。结果治疗后,联合方案组患者CD4^(+)水平及CD4^(+)/CD8^(+)均高于常规方案组,CD8^(+)水平低于常规方案组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者FAS、TuM2-PK、VEGF、CYFRA21-1、CEA、CA125水平均低于本组治疗前,联合方案组患者FAS、TuM2-PK、VEGF、CYFRA21-1、CEA、CA125水平均低于常规方案组,差异均有统计学意义(P﹤0.05)。联合方案组患者的治疗总有效率高于常规方案组,不良反应总发生率低于常规方案组,差异均有统计学意义(P﹤0.05)。结论紫杉醇脂质体联合铂类化疗治疗肺腺癌患者安全有效,能够改善免疫功能,控制病情进展,抑制肿瘤细胞生长转移,降低肿瘤标志物水平。Objective To investigate the application effect of paclitaxel liposome combined with platinum chemotherapy in patients with lung adenocarcinoma.Method A total of 80 patients with lung adenocarcinoma were divided into conventional regimen group and combined regimen group by random number table method,with 40 cases in each group.The conventional regimen group received paclitaxel combined with platinum chemotherapy,the combined regimen group received paclitaxel liposome combined with platinum chemotherapy.The CD4^(+)and CD8^(+)levels were detected by flow cytometer,and the CD4^(+)/CD8^(+)was calculated.The fatty acid synthetase(FAS)and tumor M2-pyruvate kinase(TuM2-PK)levels were detected by spectrophotometric colorimetry.The vascular endothelial growth factor(VEGF),cyto-keratin 19 fragment antigen 21-1(CYFRA21-1),carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125)levels were detected by enzyme-linked immunosorbent assay.The levels of T lymphocyte subsets(CD4^(+),CD8^(+)and CD4^(+)/CD8^(+)),FAS,TuM2-PK,VEGF,CYFRA21-1,CEA,CA125,clinical efficacy and incidence of adverse reactions were compared between the two groups.Result After treatment,the CD4^(+)level and CD4^(+)/CD8^(+)in combined regimen group were higher than those in conventional regimen group,CD8^(+)level was lower than that in conventional regimen group,and the differences were statistically significant(P<0.05).After treatment,the levels of FAS,TuM2-PK,VEGF,CYFRA21-1,CEA and CA125 in two groups were lower than those before treatment,the levels of FAS,TuM2-PK,VEGF,CYFRA21-1,CEA and CA125 in combined regimen group were lower than those in conventional regimen group,and the differences were statistically significant(P<0.05).The total effective rate of treatment in the combined regimen group was higher than that in the conventional regimen group,the total incidence of adverse reactions was lower than that in the conventional regimen group,and the differences were statistically significant(P<0.05).Conclusion The combination of paclitaxel liposome and p

关 键 词：紫杉醇脂质体 铂类化疗 肺腺癌 应用效果 

分 类 号：R734.2[医药卫生—肿瘤]